Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK1 | P06493 | 18/20 | 0.58 |
| ▸ | CDK2 | P24941 | 17/20 | 0.58 |
| ▸ | KDR | P35968 | 15/20 | 0.58 |
| ▸ | CCNB1 | P14635 | 3/20 | 0.57 |
| ▸ | CCNE1 | P24864 | 3/20 | 0.57 |
| ▸ | CA2 | P00918 | 3/20 | 0.56 |
| ▸ | CDK4 | P11802 | 2/20 | 0.56 |
| ▸ | CDK7 | P50613 | 2/20 | 0.56 |
| ▸ | CDK9 | P50750 | 2/20 | 0.56 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.56 |
| ▸ | CCND1 | P24385 | 1/20 | 0.56 |
| ▸ | CCNH | P51946 | 1/20 | 0.56 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.52 |
| ▸ | CCNA1 | P78396 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4018335 | 0.86 | CDK1 (0.62) | CDK1CDK2KDRCCNB1CCNE1 | |
| SCHEMBL24477734 | 0.81 | CDK2 (0.60) | CDK1CDK2KDRCCNB1CCNE1 | |
| SCHEMBL4019950 | 0.78 | CDK2 (0.55) | CDK1CDK2KDRCCNB1CCNE1 | |
| SCHEMBL4068152 | 0.78 | CDK2 (0.58) | CDK1CDK2KDRCCNB1CCNE1 | |
| SCHEMBL4019953 | 0.77 | CDK2 (0.51) | CDK1CDK2KDRCCNB1CCNE1 | |
| SCHEMBL3580732 | 0.75 | CDK1 (0.84) | CDK1CDK2KDRCCNB1CCNE1 | |
| SCHEMBL4061169 | 0.74 | CA2 (0.70) | CDK1CDK2KDRCCNB1CCNE1 | |
| SCHEMBL4022816 | 0.74 | CDK2 (0.55) | CDK1CDK2KDRCCNB1CCNE1 | |
| SCHEMBL4064112 | 0.73 | CDK1 (0.66) | CDK1CDK2KDRCCNB1CCNE1 | |
| SCHEMBL4061119 | 0.73 | CDK1 (0.80) | CDK1CDK2KDRCCNB1CCNE1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7598260-B2 | CDK-inhibitory pyrimidines, their production and use as pharmaceutical agents | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2009-10-06 | — | — | US | disclosed |
| US-20080039447-A1 | CDK-Inhibitory pyrimidines, their production and use as pharmaceutical agents | BRUMBY THOMAS | 2008-02-14 | — | — | US | disclosed |
| US-7291624-B2 | CDK-inhibitory pyrimidines, their production and use as pharmaceutical agents | BAYER SCHERING PHARMA AG (DE) | 2007-11-06 | — | — | US | disclosed |
| US-7235561-B2 | Compound and a composition including such a compound | SCHERING AG (DE) | 2007-06-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080039447-A1 | CDK-Inhibitory pyrimidines, their production and use as pharmaceutical agents | CDK2, CDK1, CDK6 | CDK1 2/4885CDK2 1/4885KDR 1504/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.